Ludecke Dieter K, Abe Takumi
Department of Neurosurgery, Section of Pituitary Surgery, University Clinic of Hamburg, Hamburg, Germany.
Neuroendocrinology. 2006;83(3-4):230-9. doi: 10.1159/000095533.
The aim of this short review is to inform about the possibilities and limits of transnasal microsurgery in acromegaly. The current reports on surgical remissions, according to the strict criteria with international consensus using age- and sex-related normal levels for insulin-like growth factor-I and suppression of growth hormone (GH) with oral glucose tolerance below 1 mug/l, are more or less agreeable with values between 34 and 74%. In microadenomas (<10 mm in diameter), 59-95% remissions are published. Some improvement might be achieved in macroadenomas which presently have a chance of 26-68% to be satisfactorily operated on. Special instruments introduced by us to visualize and remove partially invasive adenoma parts are described. Intraoperative magnetic resonance imaging is discussed. With intraoperative measurement of GH, small adenoma rests <3 mm can be diagnosed. When GH did not sufficiently decline, an additional tumor search resulted in a significant improvement in results in resectable macroadenomas. With these techniques, we achieved remission rates which can hardly be further increased (micros 95%, macros 68%). In grossly invasive grade 4 adenomas, which are frequent in our unit, only an 80-95% reduction in tumor mass is feasible. Preoperative treatment with somatostatin analogues as used in most of our patients reduces the comorbidity and facilitates adenoma removal which is still controversially discussed in the literature. The complication rate of microsurgery in experienced hands is low.
这篇简短综述的目的是介绍经鼻显微手术治疗肢端肥大症的可能性和局限性。目前关于手术缓解情况的报告,按照国际共识的严格标准,采用与年龄和性别相关的胰岛素样生长因子-I正常水平以及口服葡萄糖耐量试验后生长激素(GH)抑制水平低于1μg/l,缓解率大致在34%至74%之间。对于微腺瘤(直径<10mm),已发表的缓解率为59% - 95%。对于大腺瘤,目前有26% - 68%的机会得到满意的手术治疗,可能会有一些改善。文中描述了我们引入的用于可视化和切除部分侵袭性腺瘤的特殊器械。还讨论了术中磁共振成像。通过术中测量GH,可以诊断出直径<3mm的小腺瘤残留。当GH下降不充分时,再次进行肿瘤探查可显著提高可切除大腺瘤的手术效果。采用这些技术,我们实现了难以进一步提高的缓解率(微腺瘤95%,大腺瘤68%)。在我们科室常见的4级严重侵袭性腺瘤中,仅能实现肿瘤体积80% - 95%的缩小。我们大多数患者术前使用生长抑素类似物进行治疗可降低合并症,并便于腺瘤切除,这在文献中仍存在争议。在经验丰富的医生手中,显微手术的并发症发生率较低。